To understand what makes a healthy microbiome, we will be studying how the gut is initially colonised by microbes in the first months and years of life, and how this contributes to lifelong health.

Within the Quadram Institute, we are assembling an interdisciplinary team of researchers and clinicians to understand the role that our resident gut microbial community plays in determining our health. Our aims are to understand in what ways the gut microbiota help us maintain a healthy state, and the changes that occur that lead to disease. With this more mechanistic understanding of the links between gut microbes and health, we will be able to develop more effective, targeted and timely interventions to maintain health and tackle age-related diseases including cancer, cardiovascular disease, arthritis and dementia.

To understand how what makes a healthy microbiome, we will be studying how the gut is initially colonised by microbes in the first months and years of life, and how this contributes to lifelong health. We will provide a better understanding of how the mutually beneficial relationship between gut microbes and the host organism is established by defining the intercommunication and crosstalk between them, and define the mechanisms within the host that tolerate the presence of beneficial microbes.

We will establish how the microbiome influences health throughout our life, through uncovering how it influences immunity and other physiological systems such as the endocrine system and the liver. We will elucidate the microbial cues capable of driving hunger and satiety responses that influence metabolic health, and other implications of the microbiota’s interactions with the central nervous system.

We will look at how lifestyle, diet, the environment and ageing lead to changes in the microbiota, and how these changes may lead to poor health, and also how major alterations in the microbial communities link to chronic diseases. With an ageing population threatening to increase pressures on the healthcare system, we will have a particular focus on studying the decline of the microbiome during old age.

The close collaboration between researchers and clinicians within the Quadram Institute means that we can translate our fundamental new knowledge of the microbiome’s influence on health and turn it into novel therapeutics. We will be at the forefront of the development of new biomarkers for sub-optimal gut health, or microbiota-related conditions, allowing swifter diagnosis and more efficient treatment. QI’s expertise in food science will allow us to design new prebiotic or probiotic foods to maintain or restore a healthy microbiota. We will be seeking to work with the pharmaceutical industry to develop more effective, targeted drugs, as well as calling on our expertise in virology to understand the viral component of the microbiota and to develop virus-based phage therapies. And we will be looking to expand on our success by exploring the use of microbiota transplants to counter the most serious cases linked to microbes in the gut.

Realising our ambition of understanding the microbiome and developing microbiotal therapies needs the multidisciplinary approach that the Quadram Institute has brought together in one building. Microbiologists will add their knowledge of the basic biology at the cell and colony level to the genetics and genomics expertise within QI and in our partners on the Norwich Research Park. Biomathematicians and modellers will unravel the highly complex interactions between microbial species and with the host’s cells. And we have the immunologists, gut biologists and clinicians providing their understanding of the human body, which coupled with facilities for clinical trials and work with volunteer patients, brings together all the elements needed to fully explore the microbiome’s influence on health.

Research area: microbes and health
Share on FacebookTweet about this on TwitterShare on StumbleUponShare on RedditDigg thisShare on LinkedInShare on Google+Pin on PinterestEmail this to someone
Barrier loss at the tip of an intestinal villus

Watson group

Intestinal epithelium and gut health

Muller Group

Müller Group

Molecular nutrition of the gut-liver-brain axis

Webber group

Webber group

Investigating the evolution of antimicrobial resistance

Waldron group

Waldron group

Biorefining and yeast exploitation

Schuller group

Schüller group

Pathogenesis of diarrhoeagenic E. coli

Pin group

Pin group

Mathematical Biology in the Gut

Pallen group

Pallen group

Bacterial Genomics and Metagenomics

Korcsmaros group

Korcsmaros group

Systems Biology of Gut-Microbe Interactions

Juge group

Juge group

Glycobiology of host-microbe interactions in the gut

Hall Group

Hall group

Early life microbiota-host interactions

Claesen group

Claesen group

Unlocking the microbiome

Carding group

Carding group

Gut microbes in health and disease

Berazza group

Beraza group

Mechanisms regulating the gut-liver axis during health and disease

Targets

Targeting antimicrobial resistance

Antimicrobial Resistance

Targeting IBD

Inflammatory Bowel Disease (IBD)

Targeting liver disease

Liver/lipid disease

Targeting ME/CFS

ME/Chronic Fatigue Syndrome

Targeting the understanding of the microbiome

Understanding the Microbiome

Related News

QI at Invest in ME Research Conference

View

Clinical Trials Day 2017

View

Insights into the development of our second brain

View
Glial cells (pink) at the bottom of a crypt in the gut lining. Image by Aimee Parker

ME/CFS talks held in Norwich

View
Simon Carding

New evidence of how gut microbes affect Inflammatory Bowel Disease

View
Bifidobacterium breve